Q1 2025 GeneDx Holdings Corp Earnings Call Transcript
Key Points
- GeneDx Holdings Corp (WGS) reported strong first-quarter revenues exceeding $87 million, marking their third consecutive quarter of profitability.
- The company raised its full-year 2025 revenue guidance to $360 million to $375 million, reflecting confidence in continued growth.
- GeneDx's exome and genome revenues grew 62% year over year, contributing significantly to the quarter's performance.
- The company is expanding into new clinical indications and has launched an ultraRapid Genome Sequencing product with a 48-hour turnaround time.
- GeneDx announced plans to acquire Fabric Genomics, which will enhance their AI-powered genomic interpretation capabilities and add a recurring software-based revenue stream.
- The first quarter experienced a sequential decline in volumes, attributed to typical seasonality and climate disruptions in January and February.
- General and administrative expenses saw a significant increase, partly due to costs associated with the Epic integration.
- The NICU market remains mostly untapped, with expectations for volume ramping only in the second half of the year.
- There is uncertainty around the reimbursement rates for new indications, as the company awaits adjudication experience.
- Potential risks exist around Medicaid cuts, which could impact GeneDx's business given their exposure to Medicaid.
Good day, and thank you for standing by. Welcome to the GeneDx first-quarter 2025 earnings conference call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your speaker today. Sabrina Dunbar, Investor Relations. Please go ahead.
Thank you, operator, and thank you, everyone, for joining us today. On the call, we have Katherine Stueland, President and Chief Executive Officer; and Kevin Feeley, Chief Financial Officer. Earlier today, GeneDx released financial results for the first quarter ended March 31, 2025.
Before we begin, please take note of (technical difficulty) statement. We may make forward-looking statements on today's call, including about our business plans, updated 2025 guidance, and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, April 30; and we're under no obligation to update.
When discussing our results, we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
